New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.
CD25 expression has long been recognized as an adverse prognostic marker in acute leukemias including acute myeloid leukemia ...
Analysis of 2823 adult patients with acute myeloid leukemia (AML) revealed that overall survival decreases almost linearly with increasing age across all European LeukemiaNet (ELN) genetic-risk groups ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results